Last reviewed · How we verify
D660, placebo of D064, placebo of D702
D660 is a placebo control formulation with no active pharmacological mechanism.
At a glance
| Generic name | D660, placebo of D064, placebo of D702 |
|---|---|
| Also known as | D660 is consisted of antihypertensive agent. |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo of D064 and D702, D660 contains no active pharmaceutical ingredient and serves as a control comparator in clinical trials. It is designed to match the appearance and administration route of the active investigational drugs while providing no therapeutic effect, allowing for blinded assessment of efficacy and safety.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: